ID ABN80300 standard; DNA; 18679 BP.
XX
AC ABN80300;
XX
DT 15-JUL-2002 (first entry)
XX
DE Human chemically modified disease associated gene SEQ ID NO 317.
XX
KW Human; development; homeobox gene; HOX; diabetes; cancer; apoptosis;
KW heart disease; epilepsy; histone deacetylation; muscular dystrophy;
KW dwarfism; single nucleotide polymorphism; SNP; cytosine methylation;
KW antidiabetic; cytostatic; anticonvulsant; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200200927-A2.
XX
PD 03-JAN-2002.
XX
PF 02-JUL-2001; 2001WO-EP007536.
XX
PR 30-JUN-2000; 2000DE-01032529.
PR 01-SEP-2000; 2000DE-01043826.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2002-130908/17.
XX
PT Novel nucleic acid useful for diagnosis and therapy of diseases
PT associated with development genes such as diabetes, comprises a sequence
PT of a segment of chemically pretreated DNA of genes associated with
PT development.
XX
PS Claim 1; SEQ ID NO 317; 27pp; English.
XX
CC The invention relates to a nucleic acid (I) comprising a sequence at
CC least 18 bases in length of a segment of chemically pretreated DNA (II)
CC of genes associated with development selected from 87 genes listed in the
CC specification such as ACCPN, ADFN, or AFD1 and comprising one of 350
CC sequences (ABN79984-ABN80333) or their complements. The invention is
CC useful for the diagnosis or therapy of diseases associated with
CC development genes, in particular disease related to homeobox containing
CC genes (HOX), like diabetes, cancer, apoptosis related diseases, syndromes
CC associated with congenital heart disease, epilepsy, diseases related to
CC histone deacetylation, Currarino syndrome, diseases related with the
CC development of the brain and limb girdle muscular dystrophy and dwarfism.
CC Oligomers specific to each of the genes are useful for detecting the
CC methylation state of all CpG dinucleotides within the 350 sequences or
CC (II) and their complementary sequences, as primer oligonucleotides for
CC the amplification of the 350 sequences, (II) and/or their complements and
CC as oligomer probes for detecting the cytosine methylation state and/or
CC single nucleotide polymorphisms (SNPs). Note: The sequence data for this
CC patent did not form part of the printed specification but is based on
CC sequence information supplied to Derwent by the European Patent Office
XX
SQ Sequence 18679 BP; 4158 A; 716 C; 5033 G; 8772 T; 0 U; 0 Other;

Query Match 100.0%; Score 25; DB 6; Length 18679;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGTTTGTGGGTTGTTTAGTTAATGG 25
||||||||||||||||||||||||||
Db 11634 AGTTTGTGGGTTGTTTAGTTAATGG 11658

RESULT 4
ABL32050
ID ABL32050 standard; DNA; 16545 BP.
XX

ID ABN80300 standard; DNA; 18679 BP.
XX
AC ABN80300;
XX
DT 15-JUL-2002 (first entry)
XX
DE Human chemically modified disease associated gene SEQ ID NO 317.
XX
KW Human; development; homeobox gene; HOX; diabetes; cancer; apoptosis;
KW heart disease; epilepsy; histone deacetylation; muscular dystrophy;
KW dwarfism; single nucleotide polymorphism; SNP; cytosine methylation;
KW antidiabetic; cytostatic; anticonvulsant; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200200927-A2.
XX
PD 03-JAN-2002.
XX
PF 02-JUL-2001; 2001WO-EP007536.
XX
PR 30-JUN-2000; 2000DE-01032529.
PR 01-SEP-2000; 2000DE-01043826.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2002-130908/17.
XX
PT Novel nucleic acid useful for diagnosis and therapy of diseases
PT associated with development genes such as diabetes, comprises a sequence
PT of a segment of chemically pretreated DNA of genes associated with
PT development.
XX
PS Claim 1; SEQ ID NO 317; 27pp; English.
XX
CC The invention relates to a nucleic acid (I) comprising a sequence at
CC least 18 bases in length of a segment of chemically pretreated DNA (II)
CC of genes associated with development selected from 87 genes listed in the
CC specification such as ACCPN, ADFN, or AFD1 and comprising one of 350
CC sequences (ABN79984-ABN80333) or their complements. The invention is
CC useful for the diagnosis or therapy of diseases associated with
CC development genes, in particular disease related to homeobox containing
CC genes (HOX), like diabetes, cancer, apoptosis related diseases, syndromes
CC associated with congenital heart disease, epilepsy, diseases related to
CC histone deacetylation, Currarino syndrome, diseases related with the
CC development of the brain and limb girdle muscular dystrophy and dwarfism.
CC Oligomers specific to each of the genes are useful for detecting the
CC methylation state of all CpG dinucleotides within the 350 sequences or
CC (II) and their complementary sequences, as primer oligonucleotides for
CC the amplification of the 350 sequences, (II) and/or their complements and
CC as oligomer probes for detecting the cytosine methylation state and/or
CC single nucleotide polymorphisms (SNPs). Note: The sequence data for this
CC patent did not form part of the printed specification but is based on
CC sequence information supplied to Derwent by the European Patent Office
XX
SQ Sequence 18679 BP; 4158 A; 716 C; 5033 G; 8772 T; 0 U; 0 Other;

Query Match 100.0%; Score 24; DB 6; Length 18679;
Best Local Similarity 100.0%; Pred. No. 6.6;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CAAAAAATCCCAACCACCAAAACC 24
||||||||||||||||||||||||
Db 11952 CAAAAAATCCCAACCACCAAAACC 11929

RESULT 4
ABQ51324/c
ID ABQ51324 standard; DNA; 588 BP.
XX